Yevgeniy Samyshkin

959 total citations
40 papers, 717 citations indexed

About

Yevgeniy Samyshkin is a scholar working on Pulmonary and Respiratory Medicine, Economics and Econometrics and Infectious Diseases. According to data from OpenAlex, Yevgeniy Samyshkin has authored 40 papers receiving a total of 717 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 10 papers in Economics and Econometrics and 7 papers in Infectious Diseases. Recurrent topics in Yevgeniy Samyshkin's work include Health Systems, Economic Evaluations, Quality of Life (9 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers) and Diabetes Management and Research (5 papers). Yevgeniy Samyshkin is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (9 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers) and Diabetes Management and Research (5 papers). Yevgeniy Samyshkin collaborates with scholars based in United Kingdom, United States and Germany. Yevgeniy Samyshkin's co-authors include Rifat Atun, Francis Drobniewski, Ivan Fedorin, С. И. Кузнецов, Alistair McGuire, Ömer R. Saka, Nick Hex, Chris Bartlett, Mike Baxter and James Mahon and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Stroke.

In The Last Decade

Yevgeniy Samyshkin

38 papers receiving 684 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yevgeniy Samyshkin United Kingdom 17 176 167 161 137 117 40 717
Jordan K. Rosedahl United States 16 110 0.6× 208 1.2× 63 0.4× 79 0.6× 167 1.4× 35 803
Sarah Clifford United Kingdom 13 81 0.5× 92 0.6× 99 0.6× 212 1.5× 173 1.5× 22 1.4k
Ami Vyas United States 17 100 0.6× 153 0.9× 117 0.7× 190 1.4× 78 0.7× 66 864
Christopher Zacker United States 17 124 0.7× 97 0.6× 47 0.3× 244 1.8× 202 1.7× 49 1.2k
Sally A Kraft United States 13 188 1.1× 182 1.1× 56 0.3× 124 0.9× 382 3.3× 38 942
Françoise G. Pradel United States 18 206 1.2× 103 0.6× 83 0.5× 45 0.3× 157 1.3× 30 1.2k
T Volmer Germany 13 205 1.2× 119 0.7× 73 0.5× 113 0.8× 98 0.8× 26 742
Pravash Budhathoki Nepal 16 120 0.7× 74 0.4× 63 0.4× 38 0.3× 85 0.7× 85 758
Seanna Vine United States 15 97 0.6× 74 0.4× 54 0.3× 53 0.4× 99 0.8× 43 844
Pierre Lévy France 20 75 0.4× 84 0.5× 47 0.3× 222 1.6× 85 0.7× 59 919

Countries citing papers authored by Yevgeniy Samyshkin

Since Specialization
Citations

This map shows the geographic impact of Yevgeniy Samyshkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yevgeniy Samyshkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yevgeniy Samyshkin more than expected).

Fields of papers citing papers by Yevgeniy Samyshkin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yevgeniy Samyshkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yevgeniy Samyshkin. The network helps show where Yevgeniy Samyshkin may publish in the future.

Co-authorship network of co-authors of Yevgeniy Samyshkin

This figure shows the co-authorship network connecting the top 25 collaborators of Yevgeniy Samyshkin. A scholar is included among the top collaborators of Yevgeniy Samyshkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yevgeniy Samyshkin. Yevgeniy Samyshkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Iida, Shinsuke, Yevgeniy Samyshkin, Chi‐Chang Chen, et al.. (2025). Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis. PLoS ONE. 20(1). e0315932–e0315932. 2 indexed citations
2.
3.
Hogea, Cosmina, Yevgeniy Samyshkin, Eric M. Maiese, et al.. (2022). An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure. Value in Health. 25(12). 1977–1985. 1 indexed citations
4.
5.
Kiely, David G., Orla Doyle, Harvey Jenner, et al.. (2019). Utilising artificial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension. Pulmonary Circulation. 9(4). 1–9. 39 indexed citations
6.
Hoogendoorn, Martine, Talitha Feenstra, Yumi Asukai, et al.. (2017). External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. Value in Health. 20(3). 397–403. 18 indexed citations
7.
Hoogendoorn, Martine, Talitha Feenstra, Yumi Asukai, et al.. (2016). Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?. Value in Health. 19(6). 800–810. 10 indexed citations
8.
Hoogendoorn, Martine, Talitha Feenstra, Yumi Asukai, et al.. (2015). Patient Heterogeneity In Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease (Copd): are Current Models Suitable to Evaluate Personalized Medicine. Value in Health. 18(7). A694–A694. 2 indexed citations
9.
Samyshkin, Yevgeniy, et al.. (2013). Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. International Journal of COPD. 8. 79–79. 19 indexed citations
10.
Samyshkin, Yevgeniy, et al.. (2013). Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. The European Journal of Health Economics. 15(1). 69–82. 24 indexed citations
11.
12.
Lee, Won Chan, Yevgeniy Samyshkin, J Langer, & James L. Palmer. (2012). Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. Journal of Medical Economics. 15(sup2). 28–37. 25 indexed citations
13.
Samyshkin, Yevgeniy, et al.. (2012). Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. Journal of Medical Economics. 15(sup2). 6–13. 31 indexed citations
14.
Samyshkin, Yevgeniy, et al.. (2012). Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. International Journal of COPD. 7. 183–183. 41 indexed citations
15.
16.
17.
Jenkins, Rachel, Stuart Lancashire, David McDaid, et al.. (2007). Mental Health Reform in Russia –an integrated approach to achieve social inclusion and recovery. Bulletin of the World Health Organization. 1 indexed citations
18.
Atun, Rifat, Yevgeniy Samyshkin, Francis Drobniewski, et al.. (2005). Seasonal variation and hospital utilization for tuberculosis in Russia: hospitals as social care institutions. European Journal of Public Health. 15(4). 350–354. 41 indexed citations
19.
Samyshkin, Yevgeniy, et al.. (2005). Social factors influencing hospital utilisation by tuberculosis patients in the Russian Federation: analysis of routinely collected data.. PubMed. 9(10). 1140–6. 15 indexed citations
20.
Coker, R., Francis Drobniewski, Yevgeniy Samyshkin, et al.. (2005). Health system frailties in tuberculosis service provision in Russia: an analysis through the lens of formal nutritional support. Public Health. 119(9). 837–843. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jordan K. Rosedahl Breakdown of academic impact, for papers by Sarah Clifford Breakdown of academic impact, for papers by Ami Vyas Breakdown of academic impact, for papers by Christopher Zacker Breakdown of academic impact, for papers by Sally A Kraft Breakdown of academic impact, for papers by Françoise G. Pradel Breakdown of academic impact, for papers by T Volmer Breakdown of academic impact, for papers by Pravash Budhathoki Breakdown of academic impact, for papers by Seanna Vine Breakdown of academic impact, for papers by Pierre Lévy
Rankless by CCL
2026